
Biom Edit is an innovation company that discovers, designs, and develops novel microbiome-derived products to address unmet needs in animal health. They leverage the animal’s own microbial ecosystem to innovate solutions where none exist, utilizing high-throughput microbiology and AI-powered predictive algorithms to create products that prevent disease and promote health. Their unique approach to microbiome research positions them as pioneers in the field, aiming to set new standards in animal health and sustainability. With a strong foundation rooted in the history of Eli Lilly and Elanco Animal Health, Biom Edit has established significant partnerships and received recognition as a leading start-up in animal health.

Biom Edit is an innovation company that discovers, designs, and develops novel microbiome-derived products to address unmet needs in animal health. They leverage the animal’s own microbial ecosystem to innovate solutions where none exist, utilizing high-throughput microbiology and AI-powered predictive algorithms to create products that prevent disease and promote health. Their unique approach to microbiome research positions them as pioneers in the field, aiming to set new standards in animal health and sustainability. With a strong foundation rooted in the history of Eli Lilly and Elanco Animal Health, Biom Edit has established significant partnerships and received recognition as a leading start-up in animal health.
Founded: 2022
Headquarters: Fishers, Indiana
Focus: Microbiome-derived products and engineered microbial medicines for animal health
Notable product stage: BE-101 in pivotal/full pivotal development for necrotic enteritis in broiler chickens
Recent funding: Series B (2025) following earlier Series A and grants
Animal health—disease prevention and performance via microbiome modulation and engineered microbial products
2022
Biotechnology
40000000
Company completed a Series A (reported as ~$40M) and Nutreco took a minority equity stake as part of the Series A
Gates Foundation grant announced in Nov 2023
Series B raised in 2025 to advance BE-101 into pivotal development
“Backed by strategic and institutional investors including Anterra Capital, Viking Global Investors, Nutreco (minority equity), AgriZeroNZ, Elevate Ventures, Betagro Ventures, and Bill & Melinda Gates Foundation”